PURPOSE: By targeting somatostatin receptors (sst) radiopeptides have been established for both diagnosis and therapy. For physiologically normal human tissues the study provides a normative database of maximum standardized uptake value (SUV(max)) and sst mRNA. METHODS: A total of 120 patients were subjected to diagnostic (68)Ga-DOTATOC positron emission tomography (PET)/CT (age range 19-83 years). SUV(max) values were measured in physiologically normal tissues defined by normal morphology, absence of surgical intervention and absence of metastatic spread during clinical follow-up. Expression of sst subtypes (sst1-sst5) was measured independently in pooled adult normal human tissue by real-time reverse transcriptase polymerase chain reaction (RT-PCR). RESULTS: SUV(max) revealed a region-specific pattern (e.g., mean ± SD, spleen 31.1 ± 10.9, kidney 16.9 ± 5.3, liver 12.8 ± 3.6, stomach 7.0 ± 3.1, head of pancreas 6.2 ± 2.3, small bowel 4.8 ± 1.8, thyroid 4.7 ± 2.2, bone 3.9 ± 1.3, large bowel 2.9 ± 0.8, muscle 2.1 ± 0.5, parotid gland 1.9 ± 0.6, axillary lymph node 0.8 ± 0.3 and lung 0.7 ± 0.3). SUV(max) was age independent. Gender differences were evident within the thyroid (female/male: 3.7 ± 1.6/5.5 ± 2.4, p < 0.001; Mann-Whitney U test) and the pancreatic head (5.5 ± 1.9/6.9 ± 2.2, p < 0.001). The sst mRNA was widely expressed and heterogeneous, showing sst1 to be most abundant. SUV(max) values exclusively correlated with sst2 expression (r = 0.846, p < 0.001; Spearman rank correlation analysis), whereas there was no correlation of SUV(max) with the expression of the other four subtypes. CONCLUSION: In normal human tissues (68)Ga-DOTATOC imaging has been related to the expression of sst2 at the level of mRNA. The novel normative database may improve diagnostics, monitoring and therapy of sst-expressing tumours or inflammation on a molecular basis.
PURPOSE: By targeting somatostatin receptors (sst) radiopeptides have been established for both diagnosis and therapy. For physiologically normal human tissues the study provides a normative database of maximum standardized uptake value (SUV(max)) and sst mRNA. METHODS: A total of 120 patients were subjected to diagnostic (68)Ga-DOTATOC positron emission tomography (PET)/CT (age range 19-83 years). SUV(max) values were measured in physiologically normal tissues defined by normal morphology, absence of surgical intervention and absence of metastatic spread during clinical follow-up. Expression of sst subtypes (sst1-sst5) was measured independently in pooled adult normal human tissue by real-time reverse transcriptase polymerase chain reaction (RT-PCR). RESULTS: SUV(max) revealed a region-specific pattern (e.g., mean ± SD, spleen 31.1 ± 10.9, kidney 16.9 ± 5.3, liver 12.8 ± 3.6, stomach 7.0 ± 3.1, head of pancreas 6.2 ± 2.3, small bowel 4.8 ± 1.8, thyroid 4.7 ± 2.2, bone 3.9 ± 1.3, large bowel 2.9 ± 0.8, muscle 2.1 ± 0.5, parotid gland 1.9 ± 0.6, axillary lymph node 0.8 ± 0.3 and lung 0.7 ± 0.3). SUV(max) was age independent. Gender differences were evident within the thyroid (female/male: 3.7 ± 1.6/5.5 ± 2.4, p < 0.001; Mann-Whitney U test) and the pancreatic head (5.5 ± 1.9/6.9 ± 2.2, p < 0.001). The sst mRNA was widely expressed and heterogeneous, showing sst1 to be most abundant. SUV(max) values exclusively correlated with sst2 expression (r = 0.846, p < 0.001; Spearman rank correlation analysis), whereas there was no correlation of SUV(max) with the expression of the other four subtypes. CONCLUSION: In normal human tissues (68)Ga-DOTATOC imaging has been related to the expression of sst2 at the level of mRNA. The novel normative database may improve diagnostics, monitoring and therapy of sst-expressing tumours or inflammation on a molecular basis.
Authors: D Hoyer; G I Bell; M Berelowitz; J Epelbaum; W Feniuk; P P Humphrey; A M O'Carroll; Y C Patel; A Schonbrunn; J E Taylor Journal: Trends Pharmacol Sci Date: 1995-03 Impact factor: 14.819
Authors: M G Bryant; S R Bloom; J M Polak; S Hobbs; W Domschke; S Domschke; P Mitznegg; H Ruppin; L Demling Journal: Gut Date: 1983-02 Impact factor: 23.059
Authors: Sylvie Froidevaux; Alex N Eberle; Martine Christe; Lazar Sumanovski; Axel Heppeler; Jörg S Schmitt; Klaus Eisenwiener; Christoph Beglinger; Helmut R Mäcke Journal: Int J Cancer Date: 2002-04-20 Impact factor: 7.396
Authors: M Cremonesi; F Botta; A Di Dia; M Ferrari; L Bodei; C De Cicco; A Rossi; M Bartolomei; R Mei; S Severi; M Salvatori; G Pedroli; G Paganelli Journal: Q J Nucl Med Mol Imaging Date: 2010-02 Impact factor: 2.346
Authors: Daniel Putzer; Michael Gabriel; Benjamin Henninger; Dorota Kendler; Christian Uprimny; Georg Dobrozemsky; Clemens Decristoforo; Reto Josef Bale; Werner Jaschke; Irene Johanna Virgolini Journal: J Nucl Med Date: 2009-07-17 Impact factor: 10.057
Authors: Rudolf A Werner; Heribert Hänscheid; Jeffrey P Leal; Mehrbod S Javadi; Takahiro Higuchi; Martin A Lodge; Andreas K Buck; Martin G Pomper; Constantin Lapa; Steven P Rowe Journal: Mol Imaging Biol Date: 2019-08 Impact factor: 3.488
Authors: Mila V Todorović-Tirnanić; Milan M Gajić; Vladimir B Obradović; Richard P Baum Journal: Cancer Biother Radiopharm Date: 2014-01-22 Impact factor: 3.099
Authors: A Kroiss; D Putzer; C Decristoforo; C Uprimny; B Warwitz; B Nilica; M Gabriel; D Kendler; D Waitz; G Widmann; I J Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2013-01-05 Impact factor: 9.236
Authors: Akram Al-Ibraheem; Ralph Alexander Bundschuh; Johannes Notni; Andreas Buck; Anna Winter; Hans-Jürgen Wester; Markus Schwaiger; Klemens Scheidhauer Journal: Eur J Nucl Med Mol Imaging Date: 2011-07-27 Impact factor: 9.236